A patient leaves a consulting room with a prescription and a small sense of relief. Twenty minutes later, at the pharmacy counter, the relief goes. The price is higher than expected, the insurer's share is smaller than hoped, and the medicine goes back on the shelf. In the United States this happens often enough to count as a pattern, with more than four in ten adults saying cost has led them to take medicines other than as prescribed. Epic, the electronic health record supplier, has announced a feature designed to act before that moment arrives.

Prescription Marketplace, due for release in summer 2027, will let clinicians and patients at health systems using Epic compare what a drug costs at different pharmacies, with and without insurance, before the prescription is sent. Any pharmacy can share its cash prices. Amazon Pharmacy, Costco, Eli Lilly's LillyDirect and Mark Cuban Cost Plus Drugs are already involved. The tool builds on Real-Time Prescription Benefit, which shows prescribers what a patient will pay under their insurance and which Epic says saved patients more than $250 million in 2025.

The NHS does not share America's problem in any direct sense. England charges a flat fee per item with wide exemptions, and the other three nations charge nothing. Nobody in a Leeds surgery is weighing a $500 quote against a $100 one. The relevance to British health policy is structural, and it is becoming practical.

Start with the platform. Epic is now the record system in a growing number of NHS trusts, including some of the largest teaching hospitals, and the national ambition in the 10 Year Health Plan is a move from analogue to digital built around a single patient record. Those programmes tend to be judged on interoperability and clinical safety. Prescription Marketplace suggests a further test: does the record help the person it describes? Epic has taken pricing data that once sat in separate commercial systems and placed it on the screen a clinician already has open, at the moment the decision is made. Trusts that have invested heavily in the platform have good reason to ask what comparable functions could be switched on locally.

Then consider the market. A British cash market for medicines has grown quickly, driven largely by weight loss injections. A large number of people now pay privately for tirzepatide and similar drugs through online and high street pharmacies, at prices that vary and can change with little notice. NHS access to these drugs is being phased in over years, so the gap between clinical eligibility and public demand is being filled privately. Clinicians who meet these patients have no easy way to advise on cost, and patients are left to search alone. A tool that puts honest pricing inside the consultation, with pharmacies competing to be listed, addresses a need British policy has barely acknowledged. The willingness of a manufacturer such as Eli Lilly to take part through its direct-to-patient channel shows what transparency looks like when the architecture invites it.

There is a lesson here for life sciences and health-tech firms as well. Epic has opened its platform to any pharmacy that wishes to share cash prices, which makes the product a piece of market design as much as software. Access to the clinical workflow is the scarce asset for anyone hoping to reach NHS prescribers and patients. Suppliers who offer that access openly and on fair terms will shape the market, and those who guard it will watch others do so.

Cautions apply. Price is one input to prescribing, and clinical suitability and continuity of supply must always rank above it. NHS commissioners would need assurance on data governance and on how cash purchases made outside NHS dispensing appear in the record. They would also want to avoid nudging patients towards paying when an NHS route exists. Community pharmacy in England is under financial strain, and any scheme that moves demand around needs scrutiny. Each of these can be settled through careful design and early engagement with pharmacists.

The practical conclusion for NHS leaders is modest and concrete. When digital programmes are reviewed, they should ask what the record tells patients about cost, and ask their suppliers when it will be delivered. Epic has shown, in a far more expensive market than Britain's, that the answer can sit inside the workflow at scale. British trusts running its software are well placed to ask for the same.

‍